Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.

Abstract

Perivascular epithelioid cell tumor is a rare tumor. To date, there is no consensus of therapy to be recommended for unresectable disease. For a low incidence and a rarely curable disease, the finding of new therapy is essential. Here we report the first case of a patient with perivascular epithelioid cell tumor whose disease had a rapid progression after surgery and had a rapid remarkable response of combination therapy of a VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus. This result may have potential to deliver a new treatment option and inhibiting the mTOR pathway combined with inhibiting the VEGF pathways may be a useful strategy for malignant PEComas.

• Authors: Fang Gao, Chengsuo Huang, Yiping Zhang, Ruirui Sun, Yujie Zhang, Huijun Wang, Shu Zhang
• Journal: Cancer biology & therapy (Cancer Biol Ther) Vol. 17 Issue 6 Pg. 595-8 (06 02 2016) ISSN: 1555-8576 [Electronic] United States
• PMID: 27030639 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Phenylurea Compounds
• Niacinamide
• Sorafenib
• MTOR protein, human
• TOR Serine-Threonine Kinases
• Sirolimus

Topics

• Antineoplastic Agents (administration & dosage, pharmacology, therapeutic use)
• Female
• Humans
• Middle Aged
• Niacinamide (administration & dosage, analogs & derivatives, pharmacology, therapeutic use)
• Perivascular Epithelioid Cell Neoplasms (drug therapy, pathology)
• Phenylurea Compounds (administration & dosage, pharmacology, therapeutic use)
• Sirolimus (administration & dosage, pharmacology, therapeutic use)
• Sorafenib
• TOR Serine-Threonine Kinases
• Uterine Neoplasms (drug therapy, pathology)